Saw palmetto (Serenoa repens) is the most widely studied botanical remedy for benign prostatic hyperplasia (BPH) in the world. With over 30 years of peer-reviewed clinical research and more than 2 million men in the United States using it regularly, it deserves careful examination — including an honest look at both its strengths and its limitations.
Saw palmetto is a small palm native to the southeastern United States, particularly Florida and coastal Georgia. Its berry extract has been used medicinally by Native Americans for centuries and entered mainstream medical use in the 1980s when European researchers began publishing clinical data on its effects on prostate tissue.
Saw palmetto extract contains a complex of fatty acids and plant sterols that laboratory research has shown to inhibit 5-alpha reductase — the enzyme responsible for converting testosterone to dihydrotestosterone (DHT), the primary driver of prostate cell proliferation.
Unlike pharmaceutical 5-alpha reductase inhibitors (such as finasteride), saw palmetto appears to inhibit both isoforms of the enzyme (Type 1 and Type 2) while causing fewer sexual side effects — a meaningful clinical distinction that has driven continued research interest.
The research on saw palmetto is extensive but mixed — and understanding why requires looking at specific studies rather than generalizations.
Positive evidence: A 2012 Cochrane systematic review of 32 randomized controlled trials involving over 5,000 men found that saw palmetto produced modest but meaningful improvements in urinary flow rates and symptom scores compared to placebo in multiple trials. Multiple European studies — particularly from Germany and Italy where standardized extracts are regulated as medicines — have reported significant clinical improvements.
Contradictory evidence: Two large NIH-funded trials (STEP and CAMUS) found no benefit over placebo for standardized saw palmetto extract at doses of 160mg and up to 960mg daily. Critics of these trials note that the extract preparations used may not have met European pharmacopeial standards for active fatty acid content.
The critical variable appears to be extract quality and standardization. Saw palmetto extracts vary enormously in their concentration of the active liposterolic compounds (minimum 85–95% fatty acids and sterols is the European standard). Lower-quality extracts — common in the US supplement market — may explain the inconsistent results.
Based on the positive clinical evidence, the parameters that appear most relevant are:
The standard pharmaceutical approaches to BPH include alpha-blockers (tamsulosin/Flomax) and 5-alpha reductase inhibitors (finasteride/Proscar, dutasteride/Avodart). Compared to these:
Based on the available evidence, saw palmetto appears most appropriate for men with mild-to-moderate BPH symptoms who want to try natural support before considering pharmaceutical options, or men who want to complement medical treatment without significant drug interaction risk. It is not a substitute for medical evaluation or treatment of severe BPH symptoms.
Saw palmetto has 30+ years of research behind it — more than almost any other botanical for men's health. The evidence suggests real benefit for mild-to-moderate BPH when using a high-quality standardized extract at appropriate doses. Quality, standardization, and realistic expectations are the keys to meaningful results.
Take our free personalized quiz — 5 questions, 30 seconds, instant result based on your specific health profile. No email required.
Take the Free Prostate Quiz →